Greater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled study

Basit Öğe Kaydı
dc.contributor.authorInan, L. E.
dc.contributor.authorInan, N.
dc.contributor.authorKaradas, O.
dc.contributor.authorGul, H. L.
dc.contributor.authorErdemoglu, A. K.
dc.contributor.authorTurkel, Y.
dc.contributor.authorAkyol, A.
dc.date.accessioned2020-06-25T18:12:49Z
dc.date.available2020-06-25T18:12:49Z
dc.date.issued2015
dc.departmentKırıkkale Üniversitesi
dc.description.abstractObjectivesWe aimed to assess the efficacy of greater occipital nerve (GON) blockade at chronic migraine (CM) treatment. Materials and methodsPatients with CM were randomly divided into two groups of 42. GON blockade was administered four times (once per week) with saline in group A or bupivacaine in group B. After 4weeks of treatment, blinding was removed; in group A, GON blockade was achieved using bupivacaine, while group B continued to receive bupivacaine, and blockade was administered once per month, then followed for 2months. Primary endpoint was the difference in number of headache days, duration of headache, and pain scores. ResultsSeventy-two of 84 patients completed the study. After 1month of treatment, number of headache days had decreased from 16.95.7 to 13.2 +/- 6.7 in group A (P=0.035) and from 18.1 +/- 5.3 to 8.8 +/- 4.8 in group B (P<0.001), (P=0.004, between groups); duration of headache (hour) had decreased from 24.2 +/- 13.7 to 21.2 +/- 13.4 in group A (P=0.223) and from 25.9 +/- 16.3 to 19.3 +/- 11.5 in group B (P<0.001), (P=0.767, between groups). VAS score decreased from 8.1 +/- 0.9 to 6.7 +/- 1.6 in group A (P=0.002) and from 8.4 +/- 1.5 to 5.3 +/- 2.1 in group B (P<0.001), (P=0.004, between groups). After blinding was removed (in 2nd and 3rd month), group A exhibited similar results like group B in 3rd month. ConclusionsOur results suggest that GON blockade with bupivacaine was superior to placebo and was found to be effective, safe, and cost-effective for the treatment of CM. According to our knowledge, this is the first randomized, multicentre, double-blind, and placebo-controlled study in the literature in this field of work.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.doi10.1111/ane.12393
dc.identifier.endpage277en_US
dc.identifier.issn0001-6314
dc.identifier.issn1600-0404
dc.identifier.issue4en_US
dc.identifier.pmid25765043
dc.identifier.scopus2-s2.0-84940796814
dc.identifier.scopusqualityQ1
dc.identifier.startpage270en_US
dc.identifier.urihttps://doi.org/10.1111/ane.12393
dc.identifier.urihttps://hdl.handle.net/20.500.12587/6051
dc.identifier.volume132en_US
dc.identifier.wosWOS:000360801700007
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWileyen_US
dc.relation.ispartofActa Neurologica Scandinavica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmigraineen_US
dc.subjectheadacheen_US
dc.subjectgreater occipital nerve blocken_US
dc.titleGreater occipital nerve blockade for the treatment of chronic migraine: a randomized, multicenter, double-blind, and placebo-controlled studyen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Greater occipital nerve blockade for the treatment of chronic migraine a randomized, multicenter, double-blind, and placebo-controlled study.pdf
Boyut:
208.04 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu